logo
ProjectForthcoming

Delineating and eradicating cardiovascular inflammageing

Sector: Hospital • Location: Netherlands

Source: EU Funding & Tenders Portal

Atherosclerotic cardiovascular disease remains a leading global cause of morbidity and mortality, driven by inflammageing: a chronic, age-related inflammatory state accelerating atherosclerosis via epigenetic dysregulation in bone marrow immune cells, particularly hematopoietic stem and progenitor cells (HSPCs). Despite therapeutic advances, the precise mechanisms linking inflammageing to atherosc

Status
Prospective
Sector
Hospital, Nuclear
Location
Netherlands
Updated
19 Nov 2026
Source
EU Funding & Tenders Portal

ConstructChat

Ask ConstructChat about Delineating and eradicating cardiovascular inflammageing

Pick a question to edit it, or write your own.

First answer free · no account

I am a

Project Information FAQ

Project Information

3 Q
The project “Delineating and eradicating cardiovascular inflammageing” is an infrastructure initiative in the Hospital sector, located in Netherlands. Taiyo aggregates data on it from EU Funding & Tenders Portal.

Participants

Not available for this record.

Status

Original status

forthcoming

Taiyo status

Prospective

Taiyo last update

2026-11-19

Contact

Not available for this record.

Description

Description

Atherosclerotic cardiovascular disease remains a leading global cause of morbidity and mortality, driven by inflammageing: a chronic, age-related inflammatory state accelerating atherosclerosis via epigenetic dysregulation in bone marrow immune cells, particularly hematopoietic stem and progenitor cells (HSPCs). Despite therapeutic advances, the precise mechanisms linking inflammageing to atherosclerosis remain underexplored, necessitating innovative approaches to address this escalating health burden in aging populations. The DEFLAME Program, a cross-disciplinary bioengineering initiative led by Prof. Dr. Willem Mulder, is aimed at delineating the heterogeneous mechanisms of cardiovascular inflammageing across bone marrow niches to guide development of precision mRNA immunotherapy for this insidious process. Leveraging MarrowMap, a novel quantitative tool to map immune cell metabolism across multiple bone marrow niches in mouse models, and our proprietary apolipoprotein nanoparticle (aNP) mRNA delivery platform, DEFLAME integrates nanomedicine, nuclear medicine, hematopoiesis, cardiovascular immunology and multi-omics to achieve two objectives: O1 To longitudinally and spatially characterize inflammageing in atherosclerosis-accelerated immune aging, myocardial infarction, and intermittent cholesterol exposure models. O2 To develop aNP-mRNA-based cytokine and checkpoint-directed immunotherapies targeting myeloid (progenitor) cells, with translational evaluation in human cell models. By combining expertise in nanomedicine, innate immunity, and cardiovascular disease, this high-risk, high-gain ERC Advanced Grant Program seeks to reshape our understanding of immune aging and deliver innovative immunotherapeutics with potential applications beyond cardiovascular disease, including cancer and neurodegenerative disorders, fostering breakthroughs for healthy aging.

Location

Country

Netherlands

Source

Source

EU Funding & Tenders Portal

URL

More Details

Record type

Project

Sector

Hospital, Nuclear

Article published date

2026-10-15

More on this project

Research

Free account

View all details

You are reading the public part. A free account opens the rest:

  • Every detail on this project
  • News and media coverage
  • Technical research
View all details

Free account · no card · lands you back on this project